Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IB/II Study Evaluating The Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin in Combination With Rituximab (R) or Obinutuzumab (G) Plus Bendamustine (B) in Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Next Previous
Trial Profile

A Phase IB/II Study Evaluating The Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin in Combination With Rituximab (R) or Obinutuzumab (G) Plus Bendamustine (B) in Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bendamustine (Primary) ; Obinutuzumab (Primary) ; Polatuzumab vedotin (Primary) ; Rituximab (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
  • Sponsors Roche

    • Most Recent Events

    • 13 Dec 2022 Results assessing efficacy and safety (At final data cut-off October 21, 2021; safety run-in (N=6), randomized (N=40), and Ext (N=106) cohorts) of single-arm extension cohort study of GO29365 with extended follow-up of up to 5 years, including updated results from the Phase lb safety run-in, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
    • 07 Jun 2022 Results of meta-analysis of 3 randomized controlled trials (NCT01691898, NCT02257567 & NCT03274492) assessing risk of neutropenia and febrile neutropenia associated with use of polatuzumab vedotin for diffuse large B-cell lymphoma, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
    • 03 Dec 2021 Results assessing the cost-effectiveness of polatuzumab in combination with bendamustine and rituximab (BR) compared to BR in the treatment of patients with diffuse large B-cell lymphoma, in the Portuguese by deriving data from the GO29365, presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top